Renalytix: Transforming Diabetes and Kidney Disease Through Early Risk Prediction
September 12, 2020
Breaking News
The Issue
Chronic kidney disease (CKD) impacts nearly 15 million people in the US, consuming about 25% of all Medicare dollars expensed. According to independently published estimates, CKD is a significant global health issue affecting nearly 850 million individuals overall.
About Us
Renalytix plc (LSE: RENX) (OTCQB: RNLXY) is an AI-enabled diagnostics company with a mission to change how kidney disease is treated. Through its KidneyIntelXTM testing technology, the company focuses on preemptive, precision-based care in the early stages of disease, when it can have the most impact.
The company’s kidneyintelX.dkd test is the first and only authorized test to enable risk assessment (low, moderate, high) for progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease.
The test combines well-established, prognostic, blood-based biomarkers with select clinical variables and applies a machine learning derived algorithm to identify a patient’s level of risk for kidney disease progression. This enables clinicians to focus resources and guideline-recommended treatment, accordingly, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Why Renalytix and the kidneyintelX.dkd test?
- We are the founders of and global leaders in bioprognosis™ for kidney health, applying proprietary algorithms, blood-based biomarkers, genetics, and electronic health record data to forecast disease trajectories rather than just detect kidney disease.
- By using the test to risk stratify all type 2 diabetes patients with early-stage CKD, clinicians have more information to determine which patients can be maintained on their current treatment plan, who will need a little more special attention, and who will require more intensive changes in care.
- Albuminuria (UACR) and eGFR measurements are commonly used by doctors to diagnose kidney disease. Although these measurements are part of the standard of care for diagnosis, there are limitations in their use in disease prognosis. Only kidneyintelX.dkd can accurately and precisely predict disease progression over the next 5 years.
- We’re supported by an ever-growing body of test utilization evidence that demonstrates a marked increase in usage of best-in-class therapeutics, an increase in appropriate specialist referrals, and improvement in key diabetes and kidney disease metrics.
Company Highlights:
- The test is FDA-approved and recommended in the KDIGO international kidney disease guidelines.
- The test has both a national payment rate from Medicare and a final coverage determination. With that in hand, the test is covered for 60% of the eligible market.
- Renalytix is experiencing expanding commercial revenue for the test in the US and anticipates that strategic partnerships in the US and abroad will accelerate adoption of kidneyintelX.dkd.
Learn More
To learn more about Renalytix, visit renalytix.com, and for information about the kidneyintelX,dkd test, visit kidneyintelx.com. Or, contact us at investors@renalytix.com.